Premium
Open transanal resection of low rectal stromal tumor following neoadjuvant therapy of imatinib mesylate: Report of 11 cases and review of literature
Author(s) -
Sun Qiang,
Su Ning,
Li Xinxing,
Hu Zhiqian,
Wang Weijun
Publication year - 2020
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13292
Subject(s) - medicine , gist , imatinib mesylate , neoadjuvant therapy , stromal tumor , surgery , colorectal cancer , imatinib , stromal cell , cancer , breast cancer , myeloid leukemia
Objective The global burden of rectal gastrointestinal stromal tumor (GIST) is increasing. However, a limited number of reports hinder our ability to reach a definitive conclusion regarding the current treatment and prognosis. In this study, we outline our experience with open transanal resection of rectal GIST following neoadjuvant therapy with imatinib mesylate (IM). Patients and methods We retrospectively analyzed 11 patients with rectal GISTs treated with neoadjuvant IM therapy and open transanal resection between April 2011 and April 2017 in Shanghai Changzheng Hospital. Results The patients had 400–600 mg/day IM once daily for a median of 7 months (range: 3–9 months). Tumor size, distance from the lower margin of the tumor to the anal verge (AV), mitotic rates and mutation analysis were assessed on pretreatment biopsy. After reassessment, all 11 patients underwent transanal R0 resection. With median follow‐up of 28 months (range: 8–80 months), there was no tumor recurrence or metastasis. Conclusion Open transanal resection of rectal GIST after neoadjuvant treatment with IM has good surgical and survival outcomes.